Post-Transplant Cyclophosphamide Cardiac Toxicity: RN-APP Collaborative Assessment and Decision-Making.

What This Means

This research suggests that a chemotherapy drug called post-transplant cyclophosphamide (PTCy), commonly used to prevent a serious complication called graft-versus-host disease after bone marrow or stem cell transplants, can cause early heart-related problems in patients. The paper highlights the need for careful monitoring and a team-based approach involving nurses and advanced practice providers to identify and respond to these cardiac complications. The study proposes a collaborative framework where registered nurses (RNs) and advanced practice providers (APPs) work together to assess patients for signs of heart toxicity following PTCy treatment. This kind of structured teamwork may help catch cardiac problems earlier and improve decision-making in this vulnerable patient population. Note: Because the abstract provided is incomplete (truncated), the full scope of findings, specific cardiac complication rates, patient sample sizes, and detailed protocol recommendations from this paper could not be fully extracted. Readers seeking comprehensive findings should consult the full published article.